Clinical practice guidelines & test consequences 111 3 Table 2. Detailed characteristics of the CPG quality, the recommendation and the (reported) use of GRADE Guideline CPG panel Methodology (AGREE II scores) Recommendation GRADE Methodologist involvement Patient involvement (AGREE II score) Systematic evidence search methods Clear criteria for evidence selection Clear description of the strengths and limitations of the body of evidence Clear description methods for formulating recommendations Health benefits, side effects and risks have been considered Explicit link between recommendation and supporting evidence SUM score methodology domain† Direction Graded Reported use of GRADE approach Elements of GRADE approach in CPG CRP DGPB, 2016 [20] - 2 4 2 3 6 3 5 23 + + + - ACP, 2019 [21] - 5 6 5 2 6 2 6 27 + + + - MoPH, 2019 [19] - 1 2 1 2 1 1 1 8 + + - - DGPI, 2017 [22] - 2 3 1 1 7 5 2 19 - + - - Colonoscopy ESMO, 2020 [25] - 1 1 1 1 3 1 2 9 + + - - AWMF, 2019 [23] + 3 7 7 5 7 3 6 35 + - - - ACPGBI, 2017 [26] - 1 2 1 3 2 1 4 13 + + - - FMS, 2019 [24] + 5 2 1 2 4 6 7 22 + - + + NHG, 2017 [27] + 1 5 1 1 5 6 7 25 + - - - FeNO AWMF, 2020 [28] + 7 7 7 7 7 6 7 41 - + + + MoPH_A, 2019 [31] + 3 4 4 2 2 2 2 16 + - - - MoPH_C, 2019 [33] + 3 3 3 2 2 2 2 14 + + - - NAEPP, 2020 [29] + 7 7 7 7 7 7 7 42 + + + + NICE, 2020 [30]‡ + 7 7 7 7 6 7 7 41 + + + + SIGN, 2019 [32] + 7 7 3 3 4 5 7 29 + + + - +: yes; +/-: unclear; -: no; †possible range: 6-42; ‡This CPG contains two separate recommendations concerning the use of FeNO in the diagnosis of childhood respectively adult onset asthma; the scores are identical
RkJQdWJsaXNoZXIy MTk4NDMw